Antibacterial peptide composition with synergistic effect and application thereof
Through the combined use of mealworm antimicrobial peptide TmAMP1m with traditional antibiotics, the problem of drug-resistant bacteria caused by antibiotic use is solved, efficient inhibition of pathogenic microorganisms and slowing down drug resistance is achieved, and new solutions to anti-resistant pathogens are provided.
Patent Information
- Application Number
- CN202411040563.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-31
- Publication Date
- 2024-11-19
AI Technical Summary
The use of existing antibiotics has led to the emergence of drug-resistant bacteria, and the discovery of new antibiotics is slow. The combination of traditional antibiotics and antimicrobial peptides does not have synergistic effects, and there is a lack of effective solutions to antibiotic-resistant pathogens.
By expressing and purifying the antimicrobial peptide TmAMP1m of the mealworm antimicrobial peptide and using it in combination with antibiotics such as ciprofloxacin, cefepime, minocycline, ampicillin, etc., antimicrobial peptide compositions with synergistic inhibitory effects were screened for preparation of antimicrobial preparations. , preservatives and feed additives.
It has achieved efficient, safe and mild antibacterial treatment to pathogenic microorganisms such as Staphylococcus aureus and E. coli, significantly slowed down the development of drug resistance, significantly damaged the cell membrane of pathogenic microorganisms, and significantly inhibited respiratory chain dehydrogenase, providing resistance to resistance Effective strategies for drug bacteria.
Smart Images

Figure CN118976100A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of biomedicine and relates to an antimicrobial peptide composition with synergistic effect and application thereof. Background Art
[0002] The emergence of antibiotics is one of the greatest achievements in medical history. Antibiotics have helped humans overcome many diseases, but the use of antibiotics has led to the emergence of more and more drug-resistant bacteria and even superbugs. In order to fight drug-resistant bacteria, we can only look for new antibiotics, but this will produce more antibiotic-resistant bacteria, and the discovery of new antibiotics is slow. Faced with this dilemma, antimicrobial peptides are expected to become an option to fight drug-resistant pathogens.
[0003] Antimicrobial peptides (AMPs), also known as antimicrobial peptides, peptide antibiotics, and host defense peptides, are a class of small molecule polypeptides with broad-spectrum antimicrobial activity. Compared with traditional antibiotics, antimicrobial peptides produce very little drug resistance and have the potential to become a new generation of anti-infective drugs. Antimicrobial peptides have a wide range of sources, a wide variety of types, complex and diverse mechanisms of action, and are not prone to drug resistance. They have great potential to replace antibiotics. However, the shortcomings of antimicrobial peptides are also very obvious, limiting their practical application. For example: (1) Although AMPs have broad-spectrum antimicrobial activity, their overall antibacterial effect is still lower than that of traditional antibiotics; (2) The non-specific binding mode of AMPs to bacterial membranes can easily cause cytotoxicity to mammalian cells at high concentrations.
[0004] Combination therapy has been considered an effective strategy to combat the growing burden of antibiotic resistance. Compared with traditional single agents, combination therapy can synergistically improve the efficacy of each compound and overcome the shortcomings of high cost, poor efficacy, high resistance evolution rate, and severe toxic side effects of high doses. However, not all antibiotics and antimicrobial peptides have synergistic effects when used in combination, and there is a lack of mature combinations available. Therefore, research on the combined use of antibiotics and antimicrobial peptides and the discovery of synergistic antimicrobial combinations will provide a new solution for combating drug-resistant pathogens. Summary of the invention
[0005] In order to achieve safe and efficient control of pathogens and reduce the generation of drug-resistant pathogens, the present invention expresses and purifies the antimicrobial peptide TmAMP1m of Tenebrio molitor, and screens out antimicrobial peptide compositions that have a synergistic inhibitory effect on pathogenic microorganisms and are not prone to drug resistance through tests such as combined antibacterial effect and bactericidal kinetics, providing a solution to the drug-resistant bacterial crisis caused by the abuse of antibiotics. The present invention specifically provides the following technical solutions.
[0006] On the one hand, the present invention provides an antimicrobial peptide composition with synergistic effect, wherein the antimicrobial peptide composition is composed of an antimicrobial peptide TmAMP1m and an antibiotic, wherein the antibiotic is selected from: one of ciprofloxacin, cefepime, minocycline, and ampicillin.
[0007] Specifically, the antimicrobial peptide TmAMP1m and ciprofloxacin exhibited a synergistic inhibitory effect against Propionibacterium acnes.
[0008] The antimicrobial peptide TmAMP1m and cefepime showed synergistic inhibitory effect against Candida albicans.
[0009] The antimicrobial peptide TmAMP1m and minocycline showed synergistic inhibitory effects against Staphylococcus aureus, Escherichia coli, and Propionibacterium acnes.
[0010] The antimicrobial peptide TmAMP1m and ampicillin showed a synergistic inhibitory effect on Staphylococcus aureus, and in the combined system, the concentration ratio of the antimicrobial peptide TmAMP1m and ampicillin was = 285:1.
[0011] Secondly, the present invention also seeks to protect the use of the antimicrobial peptide composition in the preparation of antimicrobial preparations, which include antimicrobial preparations for human use and antimicrobial preparations for veterinary use.
[0012] In addition, the present invention also claims to protect the use of the antimicrobial peptide composition in the preparation of preservatives.
[0013] Finally, the present invention also claims protection for the use of the antimicrobial peptide composition in the preparation of feed additives.
[0014] Compared with the prior art, the present invention "an antimicrobial peptide composition with synergistic effect and its application" has the following beneficial effects or advantages.
[0015] The present invention uses the antimicrobial peptide TmAMP1m from Tenebrio molitor in combination with traditional antibiotics to screen out an antimicrobial peptide composition having a synergistic inhibitory effect on pathogenic microorganisms such as Staphylococcus aureus and Escherichia coli. The antimicrobial peptide composition has excellent antimicrobial effect and is an efficient, safe and mild antimicrobial method. Specifically, the antimicrobial peptide TmAMP1m and ciprofloxacin show a synergistic inhibitory effect on Propionibacterium acnes; the antimicrobial peptide TmAMP1m and cefepime show a synergistic inhibitory effect on Candida albicans; the antimicrobial peptide TmAMP1m and minocycline show a synergistic inhibitory effect on Staphylococcus aureus, Escherichia coli and Propionibacterium acnes; the antimicrobial peptide TmAMP1m and ampicillin show a synergistic inhibitory effect on Staphylococcus aureus.
[0016] The antimicrobial peptide composition provided by the present invention can slow down the development of drug resistance of pathogenic microorganisms. The minimum inhibitory concentration of Amp for the tested pathogenic microorganisms increased by 1,300 times, the minimum inhibitory concentration of ciprofloxacin increased to 1,024 times, the minimum inhibitory concentration of antimicrobial peptide ZY4R increased to 8 times, and the minimum inhibitory concentration of the combination group was almost unchanged, indicating that the combination of antimicrobial peptide TmAMP1m and Amp can greatly slow down the development of drug resistance of pathogenic microorganisms.
[0017] The antimicrobial peptide composition provided by the present invention has a very significant destructive effect on the cell membrane of pathogenic microorganisms. After treatment with the antimicrobial peptide TmAMP1m alone, the surface of the cell membrane of the pathogenic microorganism was slightly wrinkled, which was not full enough compared with the control group, and a few bacteria had holes and damage on the surface; after treatment with Amp alone, the cell membrane of the pathogenic microorganism was partially damaged, the cell morphology was irregular, and there was cell shrinkage; and after the antimicrobial peptide TmAMP1m was used in combination with Amp, the cell membrane destruction effect of the pathogenic microorganism was extremely significant, the cell surface was severely wrinkled, and the cells were ruptured and adhered to each other. This shows that the combined use of the antimicrobial peptide TmAMP1m and Amp has a much better destructive effect on pathogenic microorganisms than using them alone, and the killing effect on pathogenic microorganisms is more thorough in the same period of time. In addition, the crystal violet staining method and the results of the determination of the content of extracellular biomacromolecules also assisted in verifying the above conclusions.
[0018] The antimicrobial peptide composition provided by the present invention can significantly inhibit the respiratory chain dehydrogenase of pathogenic microorganisms. Compared with the control group, the absorbance of the Amp group had no significant difference, indicating that Amp had little effect on the respiratory chain dehydrogenase; the absorbance of the antimicrobial peptide TmAMP1m group decreased significantly, indicating that it had a significant inhibitory effect on the respiratory chain dehydrogenase; the absorbance of the combined group was even lower, indicating that the combined use of the antimicrobial peptide TmAMP1m and Amp enhanced the inhibitory effect on the respiratory chain dehydrogenase.
[0019] The antibacterial composition of the present invention has good application potential: based on the excellent antibacterial effect of the antibacterial peptide composition, it has good application prospects in the preparation of medicinal antibacterial preparations, preservatives, feed additives, etc., and provides an effective way to achieve the control of pathogenic microorganisms and reduce the generation of pathogenic microorganism resistance. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1 The results of induced expression and purification of the antimicrobial peptide TmAMP1m. Figure 1 In the figure, M is Marker, 1 is the sample before induction, 2 is the sample after induction, 3 is the supernatant sample after disruption, 4 is the precipitate sample after disruption, and 5 is the sample after purification.
[0021] Figure 2 This is the antibacterial activity test result of the antimicrobial peptide TmAMP1m. Figure 21 is the negative control (PBS), 2 is the positive control (Kana), 3 and 4 are the antimicrobial peptide TmAMP1m.
[0022] Figure 3 These are the bactericidal kinetic curves of Amp, antimicrobial peptide TmAMP1m and their combination.
[0023] Figure 4 This is the resistance development curve of Staphylococcus aureus under the conditions of Amp, antimicrobial peptide TmAMP1m and the combination of the two.
[0024] Figure 5 The cell morphology of Staphylococcus aureus under the conditions of Amp, antimicrobial peptide TmAMP1m and the combination of the two. Figure 5 A is the control group (no antibiotics added), B is the group using TmAMP1m alone, C is the group using Amp alone, and D is the combined group.
[0025] Figure 6 It is the residual rate of Staphylococcus aureus cell membrane under the conditions of Amp, antimicrobial peptide TmAMP1m and the combination of the two.
[0026] Figure 7 It is the absorbance value of extracellular biomacromolecules of Staphylococcus aureus under the conditions of Amp, antimicrobial peptide TmAMP1m and the combination of the two.
[0027] Figure 8 The activity of respiratory chain dehydrogenase of Staphylococcus aureus under the conditions of Amp, antimicrobial peptide TmAMP1m and the combination of the two. DETAILED DESCRIPTION
[0028] The technical solution of the present invention is clearly and completely described below in conjunction with embodiments. Obviously, the described embodiments are only a part of the embodiments of the present invention, rather than all the embodiments.
[0029] The test methods and detection methods in the following embodiments are conventional methods unless otherwise specified; the test materials used can be purchased from the market unless otherwise specified.
[0030] Example 1
[0031] This example provides the prokaryotic expression and purification of the antimicrobial peptide TmAMP1m.
[0032] The antimicrobial peptide TmAMP1m was connected to the pET-30a vector to prepare the recombinant expression vector pET-30a-TmAMP1m. The amino acid sequence, encoding gene sequence and specific method of connecting the antimicrobial peptide TmAMP1m to the pET-30a vector are all described and disclosed in detail in patent CN 102167734B.
[0033] The recombinant expression vector pET-30a-TmAMP1m was transformed into Escherichia coli BL21 competent cells, inoculated into LB solid medium containing 50 μg / mL kanamycin, and cultured at 37°C overnight.
[0034] Positive clone strains were selected and cultured at 180 rpm and 37°C for 4 h in LB liquid medium containing 50 mg / mL kanamycin; IPTG was added to a final concentration of 100 μM to induce expression for 4 h, and the positive strains without IPTG were used as blank control groups.
[0035] After induction, the cells were centrifuged at 4°C and 8000 r / min for 15 min, the bacterial pellet was resuspended and washed twice with PBS (pH = 7.4), and ultrasonically disrupted (power 200 W, work 1 s and stop 3 s), and centrifuged at 4°C and 8000 r / min for 15 min. The supernatant and precipitate were collected respectively, and the protein expression was detected by SDS-PAGE.
[0036] The antimicrobial peptide TmAMP1m was purified using a Ni column. 5-10 mL of impure protein solution containing the antimicrobial peptide TmAMP1m was added to the column, mixed at low temperature and low speed for 2 hours, and after the liquid in the column was exhausted, different concentrations of imidazole buffer were used for washing and elution. Each concentration was mixed at low temperature and low speed for 15 minutes. After that, the imidazole buffer containing the antimicrobial peptide TmAMP1m was dialyzed to remove imidazole. The dialysis time was 2 days, the total dialysate volume was 3L, and the dialysis temperature was 4°C.
[0037] Test results
[0038] The antimicrobial peptide TmAMP1m has a total of 115 amino acids and a relative molecular mass of 12.6kDa. Figure 1 The results of induced expression and purification of the antimicrobial peptide TmAMP1m. Figure 1 M is Marker, 1 is the unbroken bacterial solution before induction, 2 is the unbroken bacterial solution after induction, 3 is the supernatant after disruption, 4 is the precipitate after disruption, and 5 is the purified antimicrobial peptide TmAMP1m sample. Figure 1 In lane 3, a distinct band between 10 and 15 kDa appeared, which was consistent with the size of the antimicrobial peptide TmAMP1m from Tenebrio molitor, indicating that the protein was a soluble protein. After purification, the concentration of the antimicrobial peptide TmAMP1m was 57 μg / mL.
[0039] Example 2
[0040] This example provides an activity assay of the antimicrobial peptide TmAMP1m.
[0041] The activity of the prepared antimicrobial peptide TmAMP1m was determined using the national standard method. The activated pathogenic microorganism (Staphylococcus aureus) was diluted to 108 CFU / mL, mixed evenly with the culture medium at a volume ratio of 1:1000 and poured into a plate. After the culture medium solidified, insert the Oxford cup, add 100μL of the antimicrobial peptide TmAMP1m sample to the cup, diffuse in a 4℃ refrigerator for 4-10h, and culture in a 37℃ constant temperature incubator overnight. At the same time, 100μL of kanamycin with a concentration of 10μg / mL was used as a positive control, and 100μL of PBS was used as a negative control.
[0042] Test results
[0043] Figure 2 This is the antibacterial activity test result of the antimicrobial peptide TmAMP1m. Figure 2 As can be seen, there is no inhibition zone in the negative control group ( Figure 2 1), the positive control group produced an obvious inhibition zone ( Figure 2 2), the antimicrobial peptide TmAMP1m group also produced an inhibition zone ( Figure 2 3 and 4), indicating that the antimicrobial peptide has an antibacterial effect on Staphylococcus aureus.
[0044] Example 3
[0045] This example provides the determination of the minimum inhibitory concentration and the minimum bactericidal concentration of the antimicrobial peptide TmAMP1m.
[0046] The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) were determined by referring to the microbroth dilution method of Denardi et al. and making appropriate modifications. The pathogens to be tested (see Table 1) were diluted to 1×10 6 CFU / mL, add 100 μL of the tested pathogenic microorganism solution and 50 μL of the antimicrobial peptide TmAMP1m sample to each well of a 96-well plate, incubate at 37°C for 12 h, and then measure the OD 600 The inhibition rate was calculated, and each group of experiments was repeated three times to obtain the average value. 50 μL of 50 μg / mL kanamycin was used as a positive control, and 50 μL of PBS was used as a negative control.
[0047] The antibacterial rate calculation formula is:
[0048] Inhibition rate = (positive control OD 600 - Experimental group OD 600 ) / (positive control OD 600 - Negative control OD 600 )×100%;
[0049] When the inhibition rate is ≥50%, it is considered to have an antibacterial effect, and when the inhibition rate is ≥90%, it is considered to have a bactericidal effect. The results are shown in Table 1.
[0050] Table 1. MIC and MBC of antimicrobial peptide TmAMP1m against tested pathogenic microorganisms
[0051]
[0052]
[0053] As shown in Table 1, the antimicrobial peptide TmAMP1m has a wide range of antibacterial activity, and has significant inhibitory effects on Gram-positive bacteria (Staphylococcus aureus, Bacillus subtilis, Propionibacterium acnes), Gram-negative bacteria (Escherichia coli, Pseudomonas aeruginosa), and fungi (Candida albicans).
[0054] Example 4
[0055] This example provides the determination of the fractional inhibitory concentration (FIC) and fractional inhibitory concentration index (FICI) of the antimicrobial peptide TmAMP1m in combination with traditional antibiotics.
[0056] The chessboard method was modified to determine the combined effect of the antimicrobial peptide TmMAP1m and different antibiotics. The experimental antibiotics were: ciprofloxacin (Cip), gentamicin (GM), cefepime (FEP), minocycline (MH), ampicillin (Amp), and polymyxin B (PmB).
[0057] Add the tested pathogenic microorganisms to each well of the 96-well cell culture plate, add 100 μL of the bacterial solution, and the concentration of the bacterial solution is 1×10 6 CFU / mL. Add two antibacterial agents in the antibacterial combination along the horizontal and vertical axes, dilute in multiples (the concentration added to the next well is 1 / 2 of the previous well). Incubate at 37°C for 12-24 hours, and use an enzyme reader to measure OD 600 , calculate FIC (unit: μg / mL) and FICI:
[0058]
[0059]
[0060] FICI=FIC A +FIC B ;
[0061] MIC A / (A+B) Indicates the MIC of drug A in the combination test, MIC A represents the MIC of drug A in an independent test; MIC B / (A+B) Indicates the MIC of drug B in the combination test, MIC B The MIC of agent B in an independent experiment is shown.
[0062] When FICI≤0.5, the two antibacterial agents are considered to have a synergistic effect; when 0.5<FICI≤1, the two antibacterial agents are considered to have an enhancing effect (additive effect); when 1<FICI<4, the two antibacterial agents are considered to be unrelated; and when FICI≥4, the two antibacterial agents are considered to have an antagonistic effect.
[0063] Table 2. FICI of TmAMP1m combined with Amp
[0064] <![CDATA[MIC Amp / (Amp+TmAMP1m) ]]> 0.00625 <![CDATA[MIC Amp ]]> 0.075 <![CDATA[FIC Amp ]]> 0.0833 <![CDATA[MIC TmAMP1m / (Amp+TmAMP1m) ]]> 1.78125 <![CDATA[MIC TmAMP1m ]]> 14.25 <![CDATA[FIC TmAMP1m ]]> 0.125 FICI 0.2083 <![CDATA[MIC TmAMP1m / (Amp+TmAMP1m) :MIC Amp / (Amp+TmAMP1m) ]]> 285:1
[0065] Table 2 shows the calculation process of FICI of antimicrobial peptide TmMAP1m and ampicillin (Amp) and the concentration ratio of TmAMP1m to Amp in the combined system. As shown in Table 2, the MIC of antimicrobial peptide TmAMP1m in the combined test is 1.78125μg / mL, and the MIC of Amp in the combined test is 0.00625μg / mL. The concentration ratio of the two (ie, the MIC in the table) is TmAMP1m / (Amp+TmAMP1m) :MIC Amp / (Amp+TmAMP1m) ) is 285:1. FICI=FIC Amp +FIC TmAMP1m =0.2083. The FICI of antimicrobial peptide TmMAP1m and other antibiotics were obtained by the same method, see Table 3.
[0066] Table 3. FICI values of antimicrobial peptide TmAMP1m combined with different antibiotics
[0067]
[0068]
[0069] Note: “ / ” indicates that the pathogenic microorganism is not sensitive to antibiotics or the accurate FICI value cannot be determined due to other reasons.
[0070] As shown in Table 3, the antimicrobial peptide TmAMP1m can produce synergistic effects with some antibiotics against some pathogenic microorganisms, including: the antimicrobial peptide TmAMP1m and ciprofloxacin (Cip) show a synergistic inhibitory effect on Propionibacterium acnes; the antimicrobial peptide TmAMP1m and cefepime (FEP) show a synergistic inhibitory effect on Candida albicans; the antimicrobial peptide TmAMP1m and minocycline (MH) show a synergistic inhibitory effect on Staphylococcus aureus, Escherichia coli, and Propionibacterium acnes; the antimicrobial peptide TmAMP1m and ampicillin (Amp) show a synergistic inhibitory effect on Staphylococcus aureus.
[0071] Most of the combinations in Table 3 have an enhancement effect (additive effect), which is also important for the prevention and treatment of drug-resistant bacteria. It changes the MIC value of drug-resistant strains and reduces it from the resistant range to the sensitive range. Through this combination, antibiotics that bacteria previously developed resistance to can be used again. A small number of combinations are irrelevant, and there is no combination in Table 3 that produces an antagonistic effect.
[0072] Based on the synergistic effect of the antimicrobial peptide TmAMP1m combined with different antibiotics, the two can be further used to prepare preservatives, feed additives, etc., such as for the preservation of cosmetics and skin care products, in order to extend the shelf life or the period of use after opening. When used in the preparation of feed additives, it has positive effects such as preventing or treating certain diseases, improving animal disease resistance and feed conversion rate.
[0073] After analysis, the combination that produces the best synergistic effect is TmAMP1m and ampicillin (Amp). Amp can inhibit the synthesis of cell walls and DNA replication, interfere with bacterial protein synthesis and thus play an antibacterial role; the antibacterial effect of the antimicrobial peptide TmAMP1m is mainly concentrated on the destruction of cell membranes. The two have different targets, which may be one of the reasons why the combination produces a synergistic effect.
[0074] Example 5
[0075] This example provides the bactericidal kinetics of the antimicrobial peptide TmAMP1m combined with antibiotics.
[0076] The bactericidal kinetic curves of antibiotics and antimicrobial peptide TmAMP1m used alone and in combination were measured to reflect the combined effect. In this example, Amp was selected as the experimental antibiotic. The experimental method was based on the method of Si ngh et al. and was appropriately modified.
[0077] The experiment set up three groups, namely: control group: 500μL bacterial solution + 500μL PBS buffer; Amp group: 500μL bacterial solution + 500μL Amp (0.15μg / mL); antimicrobial peptide TmAMP1m group: 500μL bacterial solution + 500μL antimicrobial peptide TmAMP1m (28.5μg / mL), combination group: 500μL bacterial solution + 250μL Amp (0.30μg / mL) + 250μL antimicrobial peptide TmAMP1m (57μg / mL).
[0078] The tested pathogenic microorganism (Staphylococcus aureus) in the logarithmic growth phase after activation was diluted to 0.5-1×10 6CFU / mL, and then add the corresponding antibacterial components according to the above grouping. Culture at 37℃, take samples every 1h, for a total of 12h, and store in a 4℃ refrigerator after sampling. Detect the viable bacteria content on a 96-well plate, add 100μL culture medium and 50μL culture to each well, incubate at 37℃ for 2h, and measure OD 600 , according to the bacterial colony count -OD 600 The bacterial concentration was calculated from the absorbance standard curve.
[0079] Result determination: Compared with the use of each antibacterial component alone, if the logarithmic value of the concentration of the tested pathogenic microorganisms when used in combination decreases by ≥2, it is defined as a synergistic effect; if the logarithmic value of the concentration of the tested pathogenic microorganisms decreases by ≤2, it is defined as an irrelevant effect; if the logarithmic value of the concentration of the tested pathogenic microorganisms increases by ≥2, it is defined as an antagonistic effect.
[0080] The results are as follows Figure 3 Compared with the control group, the bacterial concentrations of the antimicrobial peptide TmAMP1m group and the Amp group were significantly reduced, and they had a significant inhibitory effect on pathogenic microorganisms, but they did not completely kill the pathogenic microorganisms. For the samples of the combined group for 5 hours and later, the bacterial concentration after incubation was close to 0, and it is believed that the combined group can completely kill pathogenic microorganisms for 5 hours. In addition, compared with the Amp group, which has the best antibacterial effect when used alone, the logarithmic value of the bacterial concentration in the combined group was reduced by ≥2. It can be seen that the combined use of TmAMP1m and Amp greatly improves the antibacterial ability, and both the antibacterial speed and the antibacterial thoroughness are significantly enhanced. The combined use of the two has a significant synergistic effect.
[0081] Example 6
[0082] This example provides a cell resistance development test using the antimicrobial peptide TmAMP1m in combination with Amp.
[0083] Staphylococcus aureus was used as the test pathogenic microorganism. The resistance development of antibiotics and antimicrobial peptide TmAMP1m when used alone and in combination was determined by continuous culture method according to the method of Yang et al. The minimum inhibitory concentration of different antibacterial combinations was determined, and then the minimum inhibitory concentration was measured using the bacteria in the wells with sub-inhibitory concentrations. The experiment was repeated continuously to obtain the development curve of the minimum inhibitory concentration over time.
[0084] After 30 generations of culture, the minimum inhibitory concentration of Amp against the tested pathogens increased by 1,300 times, the minimum inhibitory concentration of ciprofloxacin increased to 1,024 times, the minimum inhibitory concentration of the antimicrobial peptide ZY4R increased to 8 times, and the minimum inhibitory concentration of the combination group remained almost unchanged. Figure 4 The development of drug resistance of Staphylococcus aureus when Amp, antimicrobial peptide TmAMP1m and the combination of the two were statistically analyzed. Figure 4It can be seen that the minimum inhibitory concentration of the Amp group increased very rapidly, that is, the drug resistance developed rapidly; the minimum inhibitory concentration of the antimicrobial peptide TmAMP1m group increased less, and the minimum inhibitory concentration of the combination group remained almost unchanged, always maintaining a low level, indicating that the combination of antimicrobial peptide TmAMP1m and Amp can greatly slow the development of bacterial resistance, which is of great significance for inhibiting the occurrence and development of drug-resistant bacteria.
[0085] Example 7
[0086] This example provides scanning electron microscopy observation of the antimicrobial peptide TmAMP1m in combination with Amp.
[0087] Staphylococcus aureus was used as the test pathogenic microorganism. After culturing Staphylococcus aureus to the logarithmic growth phase, different antibacterial combinations were used for 12 hours. The sample processing method was referred to Yang et al. After the treatment, it was washed with PBS buffer, fixed with 2.5% glutaraldehyde overnight, washed again with PBS buffer, dehydrated with 50%, 70%, 80%, 90%, and 100% ethanol, stored in anhydrous ethanol, and observed by scanning electron microscopy after drying. No antibiotics were added as a control.
[0088] The results of scanning electron microscopy observations are as follows Figure 5 As shown, the surface of Staphylococcus aureus in the control group was smooth and the bacterial body was plump ( Figure 5 A in the figure); after treatment with the antimicrobial peptide TmAMP1m alone, the surface of the bacteria was slightly wrinkled and less plump than that of the control group, and a few of the bacteria had holes and damage on their surfaces ( Figure 5 B); after Amp treatment alone, the bacterial cell surface was damaged, some bacterial cells had irregular morphology, and the bacterial cell surface was wrinkled ( Figure 5 C); the combined use of antimicrobial peptide TmAMP1m and Amp had a significant effect on bacterial cell destruction, with severe cell surface shrinkage, cell rupture and mutual adhesion ( Figure 5 D).
[0089] The above results show that the combined use of antimicrobial peptide TmAMP1m and Amp has a far better destructive effect on Staphylococcus aureus than using them alone, and the killing effect on pathogenic microorganisms is more thorough in the same period of time, which is consistent with the results of the bactericidal kinetics experiment.
[0090] Example 8
[0091] This example provides the effect of the antimicrobial peptide TmAMP1m combined with Amp on the cell membrane of pathogenic microorganisms.
[0092] 1. Determination of biofilm residual rate
[0093] The crystal violet biofilm staining method was used for detection. Staphylococcus aureus was used as the test pathogenic microorganism. Staphylococcus aureus was cultured in a 96-well plate for 24 to 48 hours until the cell membrane matured. Different antibacterial combinations were added and incubated at 37°C for 4 hours. The culture medium was gently aspirated, the floating bacteria were rinsed off, methanol was added for fixation for 15 minutes, and the methanol was removed after the fixation. The cells were dried for 10 to 15 minutes. After obvious drying, 0.1% crystal violet was added for staining for 15 minutes. The cells were washed with PBS for 3 to 5 times, the excess staining solution was removed, and the crystal violet was dissolved with 33% glacial acetic acid to measure the OD. 590 .
[0094] 2. Determination of biofilm damage
[0095] Antimicrobial peptides have a destructive effect on the cell membrane, which is a barrier for substances to enter and exit the cell. Damage to the cell membrane will cause the outflow of cell contents. Therefore, the degree of cell membrane damage can be reflected by detecting the amount of extracellular biomacromolecules. Referring to the method of Yang et al. and making appropriate modifications, the activated Staphylococcus aureus was divided into 4 groups, and the following components were added in equal amounts: PBS buffer (control group), Amp (1×MIC), TmAMP1m (1×MIC), Amp+TmAMP1m (1×MIC), incubated at 37°C for 4 hours, and the OD of the supernatant was measured after centrifugation. 260 With OD 280 , O.D. 260 Represents the absorbance of nucleic acid, OD 280 Represents the absorbance of protein, OD 260 With OD 280 The larger the value, the higher the nucleic acid and protein content in the supernatant, and the higher the degree of damage to the pathogenic microorganism cells.
[0096] The results of biofilm residual rate determination are as follows Figure 6 As shown, the OD of the Amp group 590 Slightly lower than the control group, there was no significant difference between the two groups after analysis; the OD of the antimicrobial peptide TmAMP1m group 590 The OD of the combined group was significantly reduced, indicating that the antimicrobial peptide TmAMP1m has a significant destructive effect on the cell membrane of pathogenic microorganisms. 590 The results of this experiment showed that the antimicrobial peptide TmAMP1m combined with Amp had a more significant destructive effect on the cell membrane of pathogenic microorganisms, and the destructive effect of the combined use on the cell membrane was mainly attributed to the antimicrobial peptide. The formation of the cell membrane is crucial to the drug resistance of bacteria, and the results of this example well explain the differences in the results of the pathogenic microorganism resistance development test.
[0097] OD of each group 260 With OD 280 The results of the test are as follows Figure 7 As shown, compared with the control group, the OD of each test group260 With OD 280 The levels of OD in the combined group increased significantly. 260 and OD 280 The results showed that both Amp and antimicrobial peptide TmAMP1m can target and destroy the cell membrane of Staphylococcus aureus, and the combined use of the two has a more significant destructive effect.
[0098] Example 9
[0099] This example provides the effect of the antimicrobial peptide TmAMP1m combined with Amp on the respiratory chain dehydrogenase of Staphylococcus aureus.
[0100] The activity of respiratory chain dehydrogenase of Staphylococcus aureus was studied to reflect the effect of antimicrobial peptide combined with Amp on the bacterial respiratory chain. The activity of respiratory chain dehydrogenase was detected by using the property that red tetrazolium can be reduced to triphenylformazan by respiratory chain dehydrogenase. Staphylococcus aureus in the logarithmic growth phase after activation was diluted to OD 600 =0.4, the diluted bacterial solution, PBS buffer, 0.1M glucose, red tetrazolium (1mg / mL), and antibacterial components were mixed in equal amounts, incubated at 37°C for 5h, and n-butanol was added for oscillation extraction. After standing for a period of time, the supernatant was taken to measure OD 490 PBS buffer was used as a control.
[0101] After entering the cell, red tetrazolium will be reduced to red triphenylformazan by the respiratory chain dehydrogenase. The activity of the respiratory chain dehydrogenase is determined based on its content. The lower the triphenylformazan content, the lower the activity of the respiratory chain dehydrogenase. Test results ( Figure 8 ) showed that the absorbance of the Amp group had no significant difference compared with the control group, indicating that Amp had little effect on respiratory chain dehydrogenase; the absorbance of the antimicrobial peptide TmAMP1m group decreased significantly, indicating that it had a significant inhibitory effect on respiratory chain dehydrogenase; the absorbance of the combination group was even lower, which showed that the combination of antimicrobial peptide TmAMP1m and Amp had a stronger inhibitory effect on respiratory chain dehydrogenase, and TmAMP1m had the main inhibitory effect in the combination.
[0102] In summary, the present invention obtains the antimicrobial peptide TmAMP1m through prokaryotic expression, which exhibits a synergistic inhibitory effect on Propionibacterium acnes when used in combination with ciprofloxacin; exhibits a synergistic inhibitory effect on Candida albicans when used in combination with cefepime; exhibits a synergistic inhibitory effect on Staphylococcus aureus, Escherichia coli, and Propionibacterium acnes when used in combination with minocycline; exhibits a synergistic inhibitory effect on Staphylococcus aureus when used in combination with ampicillin. The antimicrobial composition provided by the present invention can slow down the development of drug resistance of pathogenic microorganisms, has a very significant destructive effect on the cell membrane of pathogenic microorganisms, and exhibits a good inhibitory effect on respiratory chain dehydrogenases, which provides an effective strategy for inhibiting the occurrence and development of drug-resistant bacteria, and can help alleviate the problem of drug resistance of pathogenic bacteria caused by abuse of antibiotics.
[0103] The above embodiments can well illustrate the technical solutions of the present invention, but they are only descriptions of the preferred implementation modes of the present invention, and do not limit the scope of the present invention. Without departing from the design spirit of the present invention, various changes and improvements made to the technical solutions of the present invention by ordinary technicians in this field should fall within the protection scope determined by the present invention.
Claims
1. An antimicrobial peptide composition with synergistic effect, characterized in that: The invention is composed of the antimicrobial peptide TmAMP1m and an antibiotic, wherein the antibiotic is selected from the group consisting of ciprofloxacin, cefepime, minocycline and ampicillin.
2. The antimicrobial peptide composition according to claim 1, characterized in that The antimicrobial peptide TmAMP1m and ciprofloxacin showed a synergistic inhibitory effect against Propionibacterium acnes.
3. The antimicrobial peptide composition according to claim 1, characterized in that The antimicrobial peptide TmAMP1m and cefepime showed synergistic inhibitory effect against Candida albicans.
4. The antimicrobial peptide composition according to claim 1, characterized in that The antimicrobial peptide TmAMP1m and minocycline showed synergistic inhibitory effects against Staphylococcus aureus, Escherichia coli, and Propionibacterium acnes.
5. The antimicrobial peptide composition according to claim 1, characterized in that The antimicrobial peptide TmAMP1m and ampicillin showed a synergistic inhibitory effect against Staphylococcus aureus.
6. The antimicrobial peptide composition according to claim 5, characterized in that: In the combined system, the concentration ratio of the antimicrobial peptide TmAMP1m and ampicillin is 285:
1.
7. Use of the antimicrobial peptide composition according to claim 1 in the preparation of an antimicrobial agent.
8. Use of the antimicrobial peptide composition according to claim 1 in the preparation of a preservative.
9. Use of the antimicrobial peptide composition according to claim 1 in the preparation of feed additives.
Citation Information
Patent Citations
Recombinant mutant tenebrio molitor antibacterial peptide and its gene and application
CN102167734B
Cited By
Antibacterial peptide GV-16 and application thereof in preparation of antibacterial drugs
CN121873187A
Antibacterial peptide composition and application thereof
CN122272765A
